Learn Why NEOX is the go-to Adjunct Therapy for Surgeons
The NEOX® line of cryopreserved umbilical cord allografts and injectables supports a regenerative healing environment and functional recovery for various wounds— ranging from common surgical wounds to complex chronic wounds.1-7
The platform technology behind the NEOX family of products promotes a healing environment for chronic and complex wounds for an overall closure rate of 87% with fewer applications and less time1, saving time and care costs.
See What Others Surgeon are Saying About NEOX
Dr. Thomas Fusco, DPM
Foot and Ankle Specialist and Podiatric Surgeon
Fort Walton Beach, FL
Dr. Thomas Fusco is a board-certified surgical podiatrist specializing in treating and repairing adult and pediatric injuries and conditions of the foot and ankle. Dr. Fusco is a wound care warrior harnessing the power of NEOX cryopreserved umbilical cord allografts. He has salvaged many limbs with NEOX and appreciates its easy handling and stays in place on the wound.
William Marston, M.D.
Professor of Surgery and Chief Division of Vascular Surgery
University of North Carolina School of Medicine
Chapel Hill, NC
Dr. William Marston is the lead investigator in the Amniox trial titled Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01) for a new investigational drug. Dr. Marston presented his 1-year follow-up results on TTAX01 in the webinar snippet above.
Javan Bass, DPM, FACFAS
Metro Foot & Ankle Centers
Dr. Javin Bass is a podiatrist and foot and ankle specialist. Dr. Bass presents his clinical experience using NEOX cryopreserved Umbilical Cord (cUC) allograft in a limb salvage to help manage complications and expedite wound healing.
Regenerative Medicine, Backed by Research
Our extensive research allows us to preserve and deliver the most functional allograft for your needs.
Research & Development
Facilitates Healing Across a Wide Range of Surgical Specialties
Minimize risk of complications, including infection and amputation1-5,9
Our platform technology, HC-HA/PTX3, supports a healing environment for wounds to achieve complete epithelization for an overall healing rate of 87.5%6
Expedite functional recovery2-16 and accelerate wound healing